Entrada Therapeutics, Inc. (NASDAQ:TRDA - Get Free Report) major shareholder Bioventures 2018 L.P. Mpm sold 22,935 shares of the company's stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $20.77, for a total value of $476,359.95. Following the completion of the sale, the insider now owns 4,402,849 shares in the company, valued at $91,447,173.73. The trade was a 0.52 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Large shareholders that own 10% or more of a company's shares are required to disclose their transactions with the SEC.
Entrada Therapeutics Trading Down 8.9 %
Shares of TRDA opened at $18.12 on Friday. The firm has a fifty day simple moving average of $18.39 and a two-hundred day simple moving average of $16.60. The firm has a market cap of $678.05 million, a PE ratio of 11.40 and a beta of -0.18. Entrada Therapeutics, Inc. has a 1-year low of $11.35 and a 1-year high of $21.79.
Institutional Inflows and Outflows
First JFK… next Elon?
From Porter & Company | Ad
Today, I have another controversial prediction.
One which I will take no pleasure in seeing come true.
See, even with President Trump returning as the leader of our free country, I believe Elon Musk is in mortal danger.
I share with you in this special investigative documentary.
A number of institutional investors have recently bought and sold shares of TRDA. Janus Henderson Group PLC boosted its holdings in shares of Entrada Therapeutics by 10.5% in the third quarter. Janus Henderson Group PLC now owns 1,711,459 shares of the company's stock worth $27,358,000 after buying an additional 161,962 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Entrada Therapeutics by 8.8% during the 3rd quarter. Geode Capital Management LLC now owns 576,451 shares of the company's stock valued at $9,214,000 after acquiring an additional 46,512 shares during the period. State Street Corp increased its stake in shares of Entrada Therapeutics by 5.5% in the 3rd quarter. State Street Corp now owns 469,601 shares of the company's stock worth $7,504,000 after purchasing an additional 24,385 shares in the last quarter. American Century Companies Inc. raised its holdings in Entrada Therapeutics by 5.1% in the 2nd quarter. American Century Companies Inc. now owns 384,973 shares of the company's stock worth $5,486,000 after purchasing an additional 18,625 shares during the period. Finally, Jacobs Levy Equity Management Inc. lifted its position in Entrada Therapeutics by 50.3% during the third quarter. Jacobs Levy Equity Management Inc. now owns 201,803 shares of the company's stock valued at $3,225,000 after purchasing an additional 67,559 shares in the last quarter. Institutional investors own 86.39% of the company's stock.
Analysts Set New Price Targets
TRDA has been the subject of several recent analyst reports. Roth Mkm started coverage on Entrada Therapeutics in a research report on Thursday, December 5th. They issued a "buy" rating and a $29.00 price target for the company. Roth Capital upgraded shares of Entrada Therapeutics to a "strong-buy" rating in a research note on Thursday, December 5th. Oppenheimer raised their price target on shares of Entrada Therapeutics from $25.00 to $28.00 and gave the company an "outperform" rating in a research report on Wednesday, November 6th. Finally, HC Wainwright upped their price objective on Entrada Therapeutics from $18.00 to $20.00 and gave the company a "buy" rating in a research report on Wednesday, November 6th.
View Our Latest Stock Analysis on Entrada Therapeutics
About Entrada Therapeutics
(
Get Free Report)
Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
